The 24 references in paper A. Budnevskiy V., A. Pertsev V., E. Ovsyannikov S., А. Будневский В., А. Перцев В., Е. Овсянников С. (2015) “Лечение и профилактика обострений хронической обструктивной болезни легких с включением эрдостеина // Treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease with erdosteine” / spz:neicon:pulmonology:y:2015:i:3:p:373-377

1
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54.
(check this in PDF content)
2
Белевский А.С., ред. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. М.: Российское респираторное общество; 2012.
(check this in PDF content)
3
Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013; 3: 5–19.
(check this in PDF content)
4
Авдеев С.Н. Новые возможности противовоспалительной терапии хронической обструктивной болезни легких. Пульмонология. 2013; 4: 95–101.
(check this in PDF content)
5
Будневский А.В., Овсянников Е.С., Чернов А.В. и др. Диагностическое значение биомаркеров системного воспаления при хронической обструктивной болезни легких. Клиническая медицина. 2014; 92 (9): 16–21.
(check this in PDF content)
6
Будневский А.В., Бурлачук В.Т., Перцев А.В. Компьютерная система мониторинга хронической обструктивной болезни легких. Пульмонология. 2014; 2: 69–72.
(check this in PDF content)
7
Будневский А.В., Овсянников Е.С., Чернов А.В. Прогностическое значение биомаркеров в оценке эффективности терапии хронической обструктивной болезни легких (обзор литературы).Молодой ученый.2014; 65 (6): 284–287.
(check this in PDF content)
8
Hasegawa K., Tsugawa Y., Tsai C.-L. et al. Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease. Respir. Res. 2014; 15: 40.
(check this in PDF content)
9
Yang H., Xiang P., Zhang E. et al. Predictors of exacerbation frequency in chronic obstructive pulmonary disease. Eur. J. Med. Res. 2014; 19: 18.
(check this in PDF content)
10
Csikesz N.G., Gartman E.J. New developments in the assessment of COPD: early diagnosis is key. Int. J. Chron. Obstruct. Pulm. Dis. 2014; (9): 277–286.
(check this in PDF content)
11
Wang Y., Stavem K., Dahl F.A. et al. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int. J. Chron. Obstruct. Pulm. Dis.2014; 9: 99–105.
(check this in PDF content)
12
Punekar Y.S., Shukla A., Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care.Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 65–73.
(check this in PDF content)
13
Solem C.T., Sun S.X., Sudharshan L. et al. Exacerbationrelated impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm.Dis. 2013; 8: 641–652.
(check this in PDF content)
14
Stafyla E. Chronic obstructive pulmonary disease exacerbation frequency and severity.Int. J. Chron. Obstruct. Pulm. Dis.2013; 8: 533–535.
(check this in PDF content)
15
Moretti M., Bottrighi P., Dallari R. et al. The effect of long term treatment with erdosteine on COPD: The EQUALIFE Study. Drugs Exp. Clin. Res. 2004; 30:143.
(check this in PDF content)
16
Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Exp. Rev. Respir. Med.2007; 1: 307–316.
(check this in PDF content)
17
Braga P.C., Dal Sasso M., Zuccotti T. Assessment of the antioxidant activity of the SH-metabolite 1 of erdosteine on human neutrophil oxidative bursts. Arzneim. Forsch. Drug Res. 2000; 50 (8): 739–746.
(check this in PDF content)
18
Dal Sasso M., Culici M., Bianchi T. et al. Inhibitory effects of metabolite 1 of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils. Pharmacology. 2004; 71: 120–127.
(check this in PDF content)
19
Hayashi H., Hosoe H., Kaise T., Ohmori K. Protective effects of Erdosteine against hypochlorus acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic inflammation in mice.J. Pharm. Pharmacol. 2000; 52: 1411–1416.
(check this in PDF content)
20
Ege E., Ilhan A., Gurel A. et al. Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia / reperfusion injury in rabbit spinal cord.Eur. J. Vasc. Endovasc.Surg. 2004; 28: 379–386.
(check this in PDF content)
21
Sener G., Sehirli A.O., Toklu H.Z. et al. Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction.Pediatr. Surg. Int.2007; 5: 123–126.
(check this in PDF content)
22
Sener G., Aksoy H.; Sehirli O et al. Erdosteine prevents colonic inflammation through its antioxidant and free radical scavenging activities. Dig. Dis. Sci.2007; 52 (9): 2122–2132.
(check this in PDF content)
23
Dal Negro R.W., Visconti M., Trevisan F. et al. Erdosteine 600 mg, but not placebo and NAC 1200 mg, restores airways response to inhaled salbutamol 200 mcg in COPD. Eur. Respir. J.2007; 30: 354.
(check this in PDF content)
24
Braga P.C., Zuccotti T., Dal Sasso M. Bacterial adhesiveness: effects of the SH-metabolite of Erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001; 47: 208–214. Поступила 05.12.14
(check this in PDF content)